+ Watch OCLS
on My Watchlist
The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.
Oculus Innovative Sciences, Inc. (OCLS) share price was high at $4.00 based on it's pipeline status. The approval of product in Mexico does little to validate it. John Ford on Seeking Alpha cites higher potential from a planned spinoff (Ruthigen IPO). Spinoffs can sometimes be lucrative, but if you're just divvying up debt, someone will lose. 1 plus 1 is still 2, not 2.5. FDA approval of a scar treatment in December doubled share price to $7, so today's prices may seem low, but you still have to market and manufacture it, generally significantly growing S&G costs/sells. An FDA approval does not mean a rich return in all cases. (DNDN).OCLS is clearly in a negative cash flow situation, requiring constant attention.Not a heavy conviction/opportunity here as catalysts, while effectively week, could cause renewed short covering, pop and drops. Looking for a retrace and a close until the dust settles again.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions